Download PDF
Diabetologie und Stoffwechsel 2021; 16(S 02): S308-S311
DOI: 10.1055/a-1581-6360
DDG-Praxisempfehlung

Diabetes und Fettleber

Norbert Stefan
1   Deutsches Zentrum für Diabetesforschung (DZD)
2   Heisenberg-Professur und Lehrstuhl für klinisch-experimentelle Diabetologie, Abteilung für Innere Medizin IV, Bereiche Endokrinologie, Diabetologie und Nephrologie, Universitätsklinikum Tübingen
3   Abteilung Pathophysiologie des Prädiabetes des Instituts für Diabetesforschung und Metabolische Erkrankungen (IDM) des Helmholtz Zentrums München an der Universität Tübingen
,
Michael Roden
1   Deutsches Zentrum für Diabetesforschung (DZD)
4   Klinik für Endokrinologie und Diabetologie, Medizinische Fakultät der Heinrich-Heine-Universität und Universitätsklinikum Düsseldorf
5   Institut für Klinische Diabetologie, Deutsches Diabetes Zentrum (DDZ), Leibniz-Zentrum für Diabetesforschung an der Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints
Aktualisierungshinweis

Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.



Publication History

Article published online:
21 October 2021

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
    CrossrefPubMedGoogle Scholar
  • 2 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol 2019; 70: 531-544
    CrossrefPubMedGoogle Scholar
  • 3 Eigentler T, Lomberg D, Machann J. et al. Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. Ann Intern Med 2020; 172: 836-837
    CrossrefPubMedGoogle Scholar
  • 4 Estes C, Anstee QM, Arias-Loste MT. et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 2018; 69: 896-904
    CrossrefPubMedGoogle Scholar
  • 5 Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7: 313-324
    CrossrefPubMedGoogle Scholar
  • 6 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
    CrossrefPubMedGoogle Scholar
  • 7 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42
    CrossrefPubMedGoogle Scholar
  • 8 European Association for the Study of the Liver (EASL); European European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
    CrossrefPubMedGoogle Scholar
  • 9 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
    CrossrefPubMedGoogle Scholar
  • 10 Bril F, McPhaul MJ, Caulfield MP. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019; 67: 303-311
    CrossrefPubMedGoogle Scholar
  • 11 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1–9
    CrossrefPubMedGoogle Scholar
  • 12 Adams LA, Anstee QM, Tilg H. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
    CrossrefPubMedGoogle Scholar